Thesis: Cellectis: the story is balanced — Clinical trial data readouts (ORR, CR rates, durability of response for UCART19/22/123 programs)
★ Analysts see FY2027 revenue reaching $117M — +99.7% growth in a single year.
What Moves the Stock 1 Clinical trial data readouts (ORR, CR rates, durability of response for UCART19/22/123 programs) 2 FDA/EMA regulatory interactions (IND clearances, clinical hold resolutions, BLA submission timelines) 3 Partnership announcements and milestone payments (licensing deals, collaboration expansions) 4 Cash position updates and financing events (equity raises, debt facilities, runway extension) 5 Competitive landscape shifts (rival allogeneic CAR-T data from Allogene, Precision BioSciences, CRISPR Therapeutics) 6 Collaboration and licensing agreements (historically ~85-90% when present, primarily Servier partnership) 7 Research grants and tax credits from French government (CIR tax credit program) 8 Potential future product sales from commercialized CAR-T therapies (not yet generating revenue) 2.5 3.0 3.6 4.1 4.6 2.84 CLLS Daily 2.84 Mar '26 Apr '26 Jun '26 Jul '26
My Notes growth - Attracts high-risk-tolerance investors seeking asymmetric returns from clinical-stage biotech with platform technology potential. Rising rates create significant headwinds through multiple channels: (1) Higher discount rates compress NPV of distant future cash flows… Watch on earnings: Quarterly cash burn rate and ending cash balance (runway calculation), Clinical trial enrollment velocity and patient dosing milestones across UCART programs, Objective response rates (ORR) and complete response (CR) rates in Phase I/II trials. One Sentence Summary: Cellectis: the story is balanced — clinical trial data readouts (orr, cr rates, durability of response for ucart19/22/123 programs).
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.